Form 4: Biohaven Director Gregory Bailey Acquires 31,716 Stock Options

Director Gregory Bailey reports acquisition of 31,716 Biohaven Ltd. stock options on May 5, 2025.

Summary

• On May 5, 2025, Gregory Bailey, a director of Biohaven Ltd., acquired 31,716 stock options.
• The exercise price of these options is $22.62.
• The options vest fully on the earlier of May 5, 2026, or the date of the 2026 Annual Meeting of Shareholders, contingent upon continuous service with the Issuer.
• The options expire on May 5, 2035.
• Following the transaction, Bailey directly owns 31,716 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition, neither particularly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon the Reporting Person's continuous service with the Issuer, suggesting an incentive for continued involvement with the company.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen often use stock options to incentivize their directors and officers.
• The vesting schedules and exercise prices are generally aligned with industry norms to ensure competitiveness and retention.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment, reflecting confidence in the company's prospects.

Key Dates

Keywords

stock options, director, Biohaven, BHVN, acquisition, Gregory Bailey, Form 4